Keywords: Aspirin, antiplatelet drugs, myocardial infarction, stroke, bleeding.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Stamler J, Vaccaro O, Neaton JD, et al. Diabtes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–444.
Zanchetti A, Hansson L, Dahlöf B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. J Hypertens 2001;19:1149–59.
Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005;165:1410–1419.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 2001;285:2486–2497.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.
Early Treatment Diabetic Retinopathy Study Report 14. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992;268:1292–1300.
Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group: Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Ophthalmology.1991;98(Suppl.):757–765.
Peto R. Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313–316.
Steering Committee of the Physicians' Health Study Research Group. Final Report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129–135.
The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulant with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233–241.
Meade TW, Brennan PJ on behalf of the MRC General Practice Research Framework. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000;321:13–17.
Hansson L, Zanchetti A, Carruthers SG et al for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755–1762.
Zanchetti A, Hansson L, Dahlöf B, et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens 2002;20:2301–2307.
Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89–95.
Ridker PJ, Cook NR, Lee IM. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Eng J Med 2005;352:1293–1304.
Chew EY, Klein ML, Murphy RP, et al.Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Arch Ophthalmol 1995;113:52–55.
Schulzer M, Mancini GBJ. “Unqualified success” and “unmitigated failure”: number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse effects. Int J Epidemiol 1996;25:704–712.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Zanchetti, A. (2007). Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes. In: Mogensen, C.E. (eds) Pharmacotherapy of Diabetes: New Developments. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69737-6_19
Download citation
DOI: https://doi.org/10.1007/978-0-387-69737-6_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-69736-9
Online ISBN: 978-0-387-69737-6
eBook Packages: MedicineMedicine (R0)